Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
European equities traded in the US as American depositary receipts started the week higher late Monday morning, rising 0.31% to 1,446.05 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma and biotech firm Evaxion Biotech , which advanced 19% and 6.7% respectively. They were followed by biopharmaceutical company Genfit and 3D printer company Materialise , which were up 5.2% and 5% respectively.
The decliners from continental Europe were led by furniture maker Natuzzi and medical device maker EDAP TMS , which fell 4% and 3.7% respectively. They were followed by biopharmaceutical companies Cellectis and Grifols , which declined 2.6% and 1.7% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical firm NuCana , which soared 150%, followed by TC Biopharm and Trinity Biotech , which were up 5.3% and 1.9%, respectively.
The decliners from the UK and Ireland were led by Bicycle Therapeutics and Biodexa Pharmaceuticals , which lost 7.5% and 4.4% respectively. They were followed by Adaptimmune Therapeutics , which was down 4.2%.
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Monday.
Shares of Alcoa Corporation rose sharply during Monday's session after the company agreed to sell its 25.1% joint venture stake in Ma’aden for $1.1 billion, including $950 million in Ma’aden shares.
Alcoa shares jumped 6.5% to $34.63 on Monday.
Here are some other big stocks recording gains in today's session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
U.S. stocks traded mixed this morning, with the Dow Jones jumping over 200 points on Monday.
Following the market opening Monday, the Dow traded up 0.54% to 41,618.01 while the NASDAQ fell 0.69% to 17,562.23. The S&P 500 also fell, dropping, 0.06% to 5,622.81.
Check This Out: This Analyst With 86% Accuracy Rate Sees Around 9% Upside In RH – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts
Leading and Lagging Sectors
Energy shares jumped by 1.7% on Monday.
In trading on Monday, information technology shares fell by 1.4%.
Top Headline
The NY Empire State Manufacturing Index rose to 11.5 in September, recording the highest level since April 2022, versus -4.7 in August and market estimates of -3.9.
Equities Trading UP
Equities Trading DOWN
Commodities
In commodity news, oil traded up 1.4% to $69.59 while gold traded down 0.1% at $2,608.10.
Silver traded up 0.7% to $31.28 on Monday, while copper rose 0.6% to $4.2630.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX fell 0.3% and France's CAC 40 fell 0.2%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.02%.
The Eurozone recorded a trade surplus of EUR 21.2 billion in July, higher than market estimates of EUR 14.9 billion. Wages in the Eurozone increased 4.5% year-over-year in the second quarter, while hourly labor costs climbed by 4.7% year-over-year in the quarter. Italy reported a trade surplus of EUR 6.743 billion in July versus a year-ago surplus of EUR 6.108 billion.
Asia Pacific Markets
Asian markets closed mostly higher on Monday, with Hong Kong's Hang Seng Index gaining 0.31% and India's BSE Sensex gaining 0.12%.
Total passenger vehicle sales in India declined 1.6% year-over-year to 308,779 in August versus a 1.9% decline in the prior month.
Economics
The NY Empire State Manufacturing Index rose to 11.5 in September, recording the highest level since April 2022, versus -4.7 in August and market estimates of -3.9.
Now Read This:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
On Saturday, NuCana plc presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy.
Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Responses.
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.
Seven of the 12 patients had a progression-free survival time of over five months.
Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma. Outcomes in this patient population are very poor, with median progression-free survival of 2-3 months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression-free survival of more than five months."
In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile.
The company says NUC-7738 can sensitize PD-1-resistant tumors to rechallenge with PD-1 inhibitors due to its ability to target multiple aspects of the tumor microenvironment (TME) via the disruption of RNA polyadenylation and subsequent changes to gene expression in cancer cells.
Data from tumor biopsies obtained before and after NUC-7738-based treatment demonstrated increases in genes related to antigen presentation and T-cell activation.
In August, NuCana discontinued NuTide:323 study following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study's primary objective of superior Progression-Free Survival compared to the control arm of 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev) in the final analysis.
Price Action: NCNA stock is up 166.50% at $6.62 during the premarket session at last check Monday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
US equity futures were mixed before the opening bell on Monday as traders awaited the Federal Reserve's regular meeting to discuss monetary policy.
Dow Jones Industrial Average futures gained 0.2%, S&P 500 futures slipped 0.1%, and Nasdaq futures declined 0.5%.
The policy-setting Federal Open Market Committee is scheduled to start its two-day meeting on Tuesday.
Oil prices were higher, with front-month global benchmark North Sea Brent crude up 1.3% at $72.52 per barrel and US West Texas Intermediate crude 1.4% higher at $68.71 per barrel.
The Empire State Manufacturing Index, released at 8:30 am ET, came in at 11.5 in September after August's negative 4.7 reading, compared with estimates compiled by Bloomberg for negative 4.0.
In other world markets, Japan's Nikkei closed 0.7% lower, Hong Kong's Hang Seng ended 0.3% higher, while the Chinese market was closed for a holiday. Meanwhile, the UK's FTSE 100 was down 0.02% and Germany's DAX index was 0.3% lower in Europe's early afternoon session.
In equities, shares of NuCana were up more than 200% pre-bell after the company said that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.